PuSH - Publikationsserver des Helmholtz Zentrums München

82 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
Alle Publikationen dieser Seite in den Korb legen
Ahuja, V.* et al.: Accuracy of 1-hour plasma glucose during the oral glucose tolerance test in diagnosis of type 2 diabetes in adults: A meta-analysis. Diabetes Care 44, 1062-1069 (2021)
Anand, V.* et al.: Islet autoimmunity and HLA markers of presymptomatic and clinical type 1 diabetes: Joint analyses of prospective cohort studies in Finland, Germany, Sweden, and the U.S. Diabetes Care, DOI: 10.2337/dc20-1836 (2021)
Bizzotto, R.* et al.: Processes underlying glycemic deterioration in type 2 diabetes: An IMI DIRECT Study. Diabetes Care 44, 511-518 (2021)
Blonde, L.* et al.: Durable effects of iGlarLixi up to 52 weeks in type 2 diabetes: The LixiLan-G Extension Study. Diabetes Care 44, 774-780 (2021)
Bonifacio, E. et al.: An age-related exponential decline in the risk of multiple islet autoantibody seroconversion during childhood. Diabetes Care, DOI: 10.2337/dc20-2122 (2021)
Canouil, M.* et al.: Epigenome-wide association study reveals methylation loci associated with offspring gestational diabetes mellitus exposure and maternal methylome. Diabetes Care 44, 1992-1999 (2021)
Kullmann, S. et al.: Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: A randomized, double-blind, placebo-controlled, phase 2 trial. Diabetes Care, DOI: 10.2337/dc21-1136 (2021)
Neuwahl, S.J.* et al.: Patient health utility equations for a type 2 diabetes model. Diabetes Care 44, 381-389 (2021)
Ng, K.* et al.: Islet autoantibody type-specific titer thresholds improve stratification of risk of progression to type 1 diabetes in children. Diabetes Care, DOI: 10.2337/dc21-0878 (2021)
Pedron, S. ; Kurz, C.F. ; Schwettmann, L. & Laxy, M.: The effect of BMI and type 2 diabetes on socioeconomic status: A two-sample multivariable mendelian randomization study. Diabetes Care 44, 850-852 (2021)
Shao, H.* et al.: Trends in total and out-of-pocket payments for noninsulin glucose-lowering drugs among U.S. adults with large-employer private health insurance from 2005 to 2018. Diabetes Care 44, 925-934 (2021)
Shao, H. et al.: Trends in total and out-of-pocket payments for insulin among privately insured U.S. adults with diabetes from 2005 to 2018. Diabetes Care 44, e1-e3 (2021)
Sujana, C. et al.: Natriuretic peptides and risk of type 2 diabetes: Results from the biomarkers for cardiovascular risk assessment in Europe (BiomarCaRE) consortium. Diabetes Care 44, 2527-2535 (2021)
Addala, A.* et al.: A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: A transatlantic comparison. Diabetes Care 44, 133-140 (2020)
Garvey, W.T.* et al.: Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care 43, 1085-1093 (2020)
Kahl, S.* et al.: Empagliflozin effectively lowers liver fat content in well-controlled Type 2 Diabetes: A randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care 43, 298-305 (2020)
Liu, X.* et al.: Distinct growth phases in early life associated with the risk of type 1 diabetes: The TEDDY study. Diabetes Care 43, 556-562 (2020)
Ochoa-Rosales, C.* et al.: Epigenetic link between statin therapy and type 2 diabetes. Diabetes Care 43, 875-884 (2020)
Soldo, J.* et al.: Increased hepatic ACE2 expression in NAFL and diabetes-A risk for COVID-19 patients? Diabetes Care 43, E134-E136 (2020)
Vehik, K.* et al.: Hierarchical order of distinct autoantibody spreading and progression to type 1 diabetes in the Teddy study. Diabetes Care 43, 2066-2073 (2020)